FrancophonIA/ELRC3.0 huggingface dataset:
English: - non-steroidal anti-inflammatory drugs - diuretic medicines (e.g. furosemide, bumetanide) - anti-cancer medicines (e.g. methotrexate, imatinib) - statins (e.g. rosuvastatin) - anti-viral medicines (e.g. oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, lamivudine,
Slovenian: • protivirusna zdravila (npr. oseltamivir, tenofovir, ganciklovir, adefovir, cidofovir, lamivudin,
English: Urinary tract infection Vaginal infection
Slovenian: Infekcijske in parazitske bolezni okužba sečil okužba nožnice
English: Vyndaqel is for oral use.
Slovenian: Zdravilo Vyndaqel je za peroralno uporabo.
English: 15 INSTRUCTIONS ON USE
Slovenian: NAVODILA ZA UPORABO
English: There is no explicit evidence of biliary excretion of tafamidis in humans.
Slovenian: Ni jasnih dokazov, da se tafamidis pri ljudeh izloča z žolčem.
English: 1 NAME OF MEDICINAL PRODUCT
Slovenian: IME ZDRAVILA
English: 5 METHOD AND ROUTE(S) OF ADMINISTRATION
Slovenian: POSTOPEK IN POT(I) UPORABE ZDRAVILA
English: Following 18 months of treatment, more tafamidis meglumine-treated patients were NIS-LL Responders (change of less than 2 points on NIS-LL) Outcomes for the pre-specified analyses of the primary endpoints are provided in the following table:
Slovenian: Po 18 mesecih zdravljenja je bilo število 'NIS-LL odzivnih bolnikov' (sprememba NIS-LL za manj kot 2 točki) večje pri bolnikih, ki so se zdravilis tafamidis megluminom.
English: Pre-specified ITT Analysis
Slovenian: Predhodno določena analiza z vključenimi bolniki (analiza ITT)
English: • You should not take Vyndaqel if you are pregnant or breast-feeding.
Slovenian: • Če ste noseči ali dojite, zdravila Vyndaqel ne smete jemati.
English: If you take more Vyndaqel than you should
Slovenian: Če ste vzeli večji odmerek zdravila Vyndaqel, kot bi smeli
English: Perforated unit dose blisters of 10 x 20 mg Vyndaqel soft capsules
Slovenian: Perforirani pretisni omoti za enkratni odmerek z 10 x 20 mg mehkimi kapsulami zdravila Vyndaqel
English: The capsule may be taken with or without food Instructions for opening the blisters
Slovenian: Kapsulo lahko vzamete skupaj s hrano ali brez nje.
English: No dosage adjustment is required for patients with renal or mild and moderate hepatic impairment.
Slovenian: Pri bolnikih z okvaro ledvic ali z blago in zmerno okvaro jeter prilagajanje odmerjanja ni potrebno.
English: Sorbitol (E420) Mannitol (E421) Titanium dioxide (E171) Purified water
Slovenian: Ovojnica kapsule želatina (E441) glicerol (E422) rumeni železov oksid (E172) sorbitan sorbitol (E420) manitol (E421) titanov dioksid (E171) prečiščena voda
English: Talk to your doctor, pharmacist or nurse before taking Vyndaqel.
Slovenian: Pred začetkom jemanja zdravila Vyndaqel se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
English: If you vomit after taking this medicine and can identify the intact Vyndaqel capsule, then an additional dose of Vyndaqel should be taken in the same day; if you cannot identify the Vyndaqel capsule, then no additional dose of Vyndaqel is necessary, and you can resume taking Vyndaqel the next day as usual.
Slovenian: Če po zaužitju tega zdravila bruhate in pri tem izbruhate nepoškodovano kapsulo zdravila Vyndaqel, v istem dnevu vzemite še en odmerek zdravila Vyndaqel.
English: Each capsule contains 20 mg tafamidis meglumine equivalent to 12.2 mg tafamidis.
Slovenian: Ena kapsula vsebuje 20 mg tafamidis meglumina, kar ustreza 12,2 mg tafamidisa.
English: INNER CARTON
Slovenian: NOTRANJA ŠKATLA
English: Each soft capsule contains 20 mg of micronized tafamidis meglumine equivalent to 12.2 mg tafamidis.
Slovenian: Ena mehka kapsula vsebuje 20 mg mikroniziranega tafamidis meglumina, kar ustreza 12,2 mg tafamidisa.
English: Multipack: 90 (3 packs of 30 x 1) soft capsules.
Slovenian: skupno pakiranje: 90 (3 pakiranja po 30 x 1) mehkih kapsul
English: NIS-LL Responders (% Patients) Difference (Vyndaqel minus Placebo) 95% CI of Difference (p-value) TQOL Change from Baseline LSMean (SE) Difference in LSMeans (SE) 95% CI of Difference (p-value) Pre-specified Efficacy Evaluable Analysis
Slovenian: NIS-LL odzivni bolniki (% bolnikov) Razlika (Vyndaqel minus placebo) 95 % IZ pri razliki (vrednost p) Sprememba skupne ocene kakovosti življenja [TQOL] glede na izhodišče - povprečje najmanjših kvadratov (standardna napaka [SE]) Razlika v povprečju najmanjših kvadratov (standardna napaka [SE]) 95 % IZ pri razliki (vrednost p) Predhodno določena analiza učinkovitosti, ki jo je mogoče ovrednotiti n = 42
English: What Vyndaqel contains
Slovenian: Kaj vsebuje zdravilo Vyndaqel
English: Pack of 30 - for multipack of 90 (3 packs of 30 x 1) soft capsules - WITHOUT BLUE BOX
Slovenian: Pakiranje po 30 - skupno pakiranje po 90 (3 pakiranja po 30 x 1) mehkih kapsul - BREZ MODREGA OKENCA
English: Printing ink (Opacode purple) Ethyl alcohol
Slovenian: Črnilo (Opacode vijoličasto)
English: Each soft capsule contains 20 mg tafamidis meglumine equivalent to 12.2 mg tafamidis
Slovenian: Ena mehka kapsula vsebuje 20 mg tafamidis meglumina, kar ustreza 12,2 mg tafamidisa.
English: Multipack of 90 (3 packs of 30 x 1) soft capsules - WITH BLUE BOX
Slovenian: Skupno pakiranje po 90 (3 pakiranja po 30 x 1) mehkih kapsul - Z MODRIM OKENCEM
English: 2 STATEMENT OF ACTIVE SUBSTANCES
Slovenian: SEZNAM POMOŽNIH SNOVI
English: The exposure to tafamidis in patients with severe hepatic impairment is unknown.
Slovenian: Pri bolnikih s hudo okvaro jeter ni podatkov o izpostavljenosti tafamidisu.
English: 3 EXPIRY DATE
Slovenian: Do datuma
English: 2 NAME OF THE MARKETING AUTHORISATION HOLDER
Slovenian: IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: What Vyndaqel is and what it is used for
Slovenian: Kaj je zdravilo Vyndaqel in za kaj ga uporabljamo
English: 8 MARKETING AUTHORISATION NUMBER(S) EU/1/11/717/001
Slovenian: EU/1/11/717/001 EU/1/11/717/002
English: zidovudine, zalcitabine)
Slovenian: • statine (npr. rosuvastatin)
English: There are also links to other websites about rare diseases and treatments.
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu, kjer so na voljo tudi povezave do drugih spletnih strani o redkih boleznih in zdravljenju.
English: Gastrointestinal disorders
Slovenian: Navodila za odpiranje pretisnih omotov
English: 4 BATCH NUMBER
Slovenian: Številka serije
English: NIS-LL change from BL LSMean (SE)
Slovenian: Sprememba pri NIS-LL glede na izhodišče
English: 6 PHARMACEUTICAL PARTICULARS
Slovenian: Posebne skupine bolnikov
English: Macrogol 400 (E1521) Polyvinyl acetate phthalate Propylene glycol (E1520) Carmine (E120)
Slovenian: etanol izopropilalkohol prečiščena voda makrogol 400 (E1521)
English: 13 BATCH NUMBER
Slovenian: ŠTEVILKA SERIJE
English: United Kingdom
Slovenian: Velika Britanija ali
English: Further information on Riximyo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Riximyo.
Slovenian: Nadaljnje informacije za zdravilo Riximyo so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Riximyo.
English: Riximyo received a marketing authorisation valid throughout the EU on 15 June 2017.
Slovenian: Za zdravilo Riximyo je bilo 15. junija 2017 izdano dovoljenje za promet, veljavno po vsej EU.
English: The cancer improved in just over 87% of those given Riximyo (271 of 311 patients), and in similar numbers of those given MabThera (274 of 313 patients).
Slovenian: Rak se je odzval na zdravljenje pri nekaj več kot 87 % (271 od 311) bolnikov, ki so prejemali zdravilo Riximyo, in pri podobnem številu bolnikov, ki so prejemali zdravilo MabThera (274 od 313 bolnikov).
English: This means that Riximyo is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Slovenian: To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
English: What measures are being taken to ensure the safe and effective use of Riximyo?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Riximyo?
English: Riximyo (rituximab)
Slovenian: Riximyo (rituksimab)
English: The company marketing Riximyo will provide doctors with additional information about giving the medicine correctly.
Slovenian: Podjetje, ki trži zdravilo Riximyo, bo zdravnikom priskrbelo dodatno informativno gradivo o pravilnem dajanju zdravila.
English: An overview of Riximyo and why it is authorised in the EU
Slovenian: Pregled zdravila Riximyo in zakaj je odobreno v EU
English: Riximyo is a medicine used in adults to treat the following blood cancers and inflammatory conditions:
Slovenian: Riximyo je zdravilo, ki se uporablja za zdravljenje naslednjih vrst krvnega raka in vnetnih bolezni pri odraslih:
English: Side effects reported with Riximyo are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Riximyo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: As for all medicines, data on the use of Riximyo are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Riximyo stalno spremljajo.
English: Why is Riximyo authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Riximyo odobreno v EU?
English: For more information about using Riximyo, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij o uporabi zdravila Riximyo glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: What benefits of Riximyo have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Riximyo izkazalo v študijah?
English: Riximyo must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients or in patients with a severe infection or a severely weakened immune system (the body's defences).
Slovenian: Zdravilo Riximyo se ne sme uporabljati pri osebah, ki so preobčutljive za (alergične na) rituksimab, mišje beljakovine ali katero koli drugo sestavino zdravila, ali bolniki s hudo okužbo ali močno oslabljenim imunskim sistemom (obrambnim mehanizmom telesa).
English: The most common side effects with Riximyo are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heartrelated problems.
Slovenian: Najpogostejši neželeni učinki zdravila Riximyo so reakcije, povezane z infuzijo (kot so povišana telesna temperatura, mrzlica in drgetanje), najpogostejši resni neželeni učinki pa so reakcije, povezane z infuzijo, okužbe in težave, povezane s srcem.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Riximyo have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Riximyo upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Other information about Riximyo
Slovenian: Druge informacije o zdravilu Riximyo
English: Patients with GPA, MPA or pemphigus vulgaris must also not receive Riximyo if they have severe heart problems.
Slovenian: Bolniki z Wegenerjevo granulomatozo, mikroskopskim poliangiitisom ali navadnim pemfigusom prav tako ne smejo prejemati zdravila Riximyo, če imajo hude težave s srcem.
English: It will also provide doctors and patients using the medicine for GPA, MPA or pemphigus with educational material on the risk of infection including that of a rare severe infection, progressive multifocal leukoencephalopathy (PML).
Slovenian: Zdravnikom in bolnikom, ki uporabljajo zdravilo za zdravljenje Wegenerjeve granulomatoze, mikroskopskega poliangiitisa ali navadnega pemfigusa, bo priskrbelo tudi izobraževalno gradivo o tveganju za okužbe, vključno s hudo redko okužbo, znano kot progresivna multifokalna levkoencefalopatija (PML).
English: In addition, Riximyo was as effective as MabThera in one main study involving 629 patients with advanced, untreated follicular lymphoma, where Riximyo or MabThera were added to other chemotherapy for part of the treatment.
Slovenian: Poleg tega se je zdravilo Riximyo izkazalo za enako učinkovito kot zdravilo MabThera v eni glavni študiji, ki je vključevala 629 bolnikov z napredovalim, nezdravljenim folikularnim limfomom, v kateri so v določenem obdobju zdravljenja zdravilo Riximyo ali MabThera dodali k drugi vrsti kemoterapije.
English: What is Riximyo and what is it used for?
Slovenian: Kaj je zdravilo Riximyo in za kaj se uporablja?
English: What are the risks associated with Riximyo?
Slovenian: Kakšna tveganja so povezana z zdravilom Riximyo?
English: Depending on the condition it is used to treat, Riximyo may be given on its own, or with chemotherapy (cancer medicines) or medicines used for inflammatory disorders (methotrexate or a corticosteroid).
Slovenian: Zdravilo Riximyo se lahko odvisno od stanja, za katero se uporablja, daje samostojno, skupaj s kemoterapijo (zdravili za zdravljenje raka) ali z zdravili za zdravljenje vnetnih bolezni (metotreksatom ali kortikosteroidom).
English: In GPA and MPA, destroying B cells lowers the production of antibodies thought to play an important role in attacking the blood vessels and causing inflammation.
Slovenian: Pri Wegenerjevi granulomatozi in mikroskopskem poliangiitisu se z uničenjem celic B zmanjša tvorba protiteles, ki naj bi imela pomembno vlogo pri napadanju krvnih žil in povzročanju vnetja.
English: The safety of Riximyo has been evaluated, and on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine MabThera.
Slovenian: Varnost zdravila Riximyo je bila ocenjena, na podlagi vseh izvedenih študij pa so bili neželeni učinki zdravila ocenjeni kot primerljivi z neželenimi učinki referenčnega zdravila MabThera.
English: The reference medicine for Riximyo is MabThera.
Slovenian: Referenčno zdravilo za zdravilo Riximyo je zdravilo MabThera.
English: All these data were considered sufficient to conclude that Riximyo will behave in the same way as MabThera in terms of effectiveness and safety in its authorised uses.
Slovenian: Vsi ti podatki so bili ocenjeni kot zadostni za zaključek, da se bo zdravilo Riximyo pri odobrenih uporabah z vidika učinkovitosti in varnosti vedlo enako kot zdravilo MabThera.
English: For the full list of side effects and restrictions of Riximyo, see the package leaflet.
Slovenian: Za celotni seznam neželenih učinkov in omejitev pri uporabi zdravila Riximyo glejte navodilo za uporabo.
English: Therefore, the Agency's view was that, as for MabThera, the benefits of Riximyo outweigh the identified risks and it can be authorised for use in the EU.
Slovenian: Zato je agencija menila, da koristi zdravila Riximyo enako kot pri zdravilu MabThera odtehtajo znana tveganja in da se zdravilo lahko odobri za uporabo v EU.
English: In addition, a study in patients with follicular lymphoma has shown that the safety and effectiveness of Riximyo are equivalent to those of MabThera.
Slovenian: Poleg tega je študija pri bolnikih s folikularnim limfomom pokazala, da sta varnost in učinkovitost zdravila Riximyo enaki kot pri zdravilu MabThera.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Riximyo has a highly similar structure, purity and biological activity to MabThera and is distributed in the body in the same way.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Riximyo po zgradbi, čistosti in biološkem delovanju zelo podobno zdravilu MabThera in da se po telesu enako porazdeli.
English: Because Riximyo is a biosimilar medicine, the studies on effectiveness and safety of rituximab carried out with MabThera do not all need to be repeated for Riximyo.
Slovenian: Zdravilo Riximyo je „podobno biološko zdravilo“, zato študij o učinkovitosti in varnosti rituksimaba, izvedenih z zdravilom MabThera, z zdravilom Riximyo ni treba ponavljati.
English: Laboratory studies comparing Riximyo with the reference medicine MabThera have shown that the active substance in Riximyo is highly similar to that in MabThera in terms of structure, purity and biological activity.
Slovenian: Laboratorijske študije, v katerih so zdravilo Riximyo primerjali z referenčnim zdravilom MabThera, so pokazale, da je učinkovina v zdravilu Riximyo po zgradbi, čistosti in biološkem delovanju zelo podobna učinkovini v zdravilu MabThera.
English: How is Riximyo used?
Slovenian: Kako se zdravilo Riximyo uporablja?
English: Riximyo is a ‘biosimilar medicine'.
Slovenian: Zdravilo Riximyo je „podobno biološko zdravilo“.
English: How does Riximyo work?
Slovenian: Kako zdravilo Riximyo deluje?
English: When rituximab attaches to CD20, it causes the B cells to die, which helps in lymphoma and CLL (where B cells have become cancerous) and in pemphigus (where B cells are involved in inflammation).
Slovenian: Učinkovina v zdravilu Riximyo, rituksimab, je monoklonsko protitelo, ki je zasnovano tako, da se veže na beljakovino, imenovano CD20, ki se nahaja na površini celic B. Rituksimab z vezavo na CD20 povzroči, da celice B odmrejo, kar pripomore pri zdravljenju limfoma in kronične limfocitne levkemije (pri katerih so celice B postale rakaste) ter pemfigusa (pri katerem celice B sodelujejo pri vnetju).
English: Riximyo can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila Riximyo je le na recept.
English: Riximyo contains the active substance rituximab.
Slovenian: Zdravilo Riximyo vsebuje učinkovino rituksimab.
English: Studies have also shown that giving Riximyo produces similar levels of the active substance in the body to giving MabThera.
Slovenian: Študije so pokazale tudi, da je količina učinkovine v telesu pri zdravilu Riximyo podobna kot pri zdravilu MabThera.
English: With regard to safety, no major issues were identified and side effects were manageable.
Slovenian: Kar zadeva varnost, ni bilo ugotovljenih večjih težav, neželeni učinki pa so bili obvladljivi.
English: The full EPAR and risk management plan summary for Episalvan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Episalvan sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Episalvan?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Episalvan?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Episalvan's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zato zaključil, da so koristi zdravila Episalvan večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: This is a summary of the European public assessment report (EPAR) for Episalvan.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Episalvan.
English: Other information about Episalvan
Slovenian: Druge informacije o zdravilu Episalvan
English: The exact way Episalvan works is not fully understood.
Slovenian: Točno delovanje zdravila Episalvan ni v celoti znano.
English: A risk management plan has been developed to ensure that Episalvan is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Episalvan je bil pripravljen načrt obvladovanja tveganj.
English: Both wound halves were also covered with a wound dressing.
Slovenian: Obe polovici rane so pokrili tudi s povojem.
English: The respective times were 16.0 and 15.1 days respectively in the second study.
Slovenian: V drugi študiji je bil ta čas 16,0 oziroma 15,1 dneva.
English: Although the differences were small they were considered relevant for patients with partial-thickness wounds, which can be difficult to heal and for which treatment options are limited.
Slovenian: Čeprav so bile razlike majhne, so za bolnike z ranami delne debeline kože pomembne, saj se te rane težko celijo, možnosti zdravljenja pa so omejene.
English: These are wounds where the upper layers of the skin have been lost, for example by a burn or during surgical skin grafting.
Slovenian: To so rane, pri katerih zgornje plasti kože ni več, na primer zaradi opekline ali kirurške presaditve kože.
English: It is not intended to provide practical advice on how to use Episalvan.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The most common side effects with Episalvan are wound complications, pain in the skin (both of which may affect more than 3 in 100 people) and pruritus (itching) (which may affect more 1 in 100 people).
Slovenian: Najpogostejši neželeni učinki zdravila Episalvan so zapleti pri rani, bolečine na koži (ki lahko prizadeneta več kot 3 osebe od 100) in pruritus (srbenje) (ki lahko prizadene več kot 1 osebo od 100).
English: Why is Episalvan approved?
Slovenian: Zakaj je bilo zdravilo Episalvan odobreno?
English: What benefits of Episalvan have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Episalvan izkazalo v študijah?
English: For more information about treatment with Episalvan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Episalvan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What are the risks associated with Episalvan?
Slovenian: Kakšna tveganja so povezana z zdravilom Episalvan?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Episalvan, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Episalvan in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For the full list of all side effects and restrictions reported with Episalvan, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev, o katerih so poročali pri uporabi zdravila Episalvan, glejte navodilo za uporabo.
English: Episalvan was studied in two main studies involving 217 patients with partial-thickness skin wounds in patients who underwent skin graft surgery.
Slovenian: Zdravilo Episalvan so proučevali v dveh glavnih študijah, v kateri je bilo vključenih 217 bolnikov z ranami delne debeline kože, ki so prestali kirurški poseg za odvzem presadka.
English: What is Episalvan and what is it used for?
Slovenian: Kaj je zdravilo Episalvan in za kaj se uporablja?
English: The gel should be re-applied with every dressing change, until the wound is healed, for up to 4 weeks.
Slovenian: Gel je treba do 4 tedne ponovno nanesti pri vsakem previjanju rane, dokler ni rana zaceljena.
English: It is thought that the active substance in Episalvan, birch bark extract, helps the cells that make up the outer layer of the skin (keratinocytes) grow and move quickly towards the gap created by the wound, therefore helping wounds to heal faster.
Slovenian: Domneva se, da zdravilna učinkovina zdravila Episalvan, ekstrakt skorje breze, pomaga pri rasti celic, ki sestavljajo zunanjo plast kože (keratinocitom), in njihovem hitrejšem premikanju proti vrzeli, ki je nastala zaradi rane, ter tako pripomore k hitrejšemu celjenju rane.
English: For practical information about using Episalvan, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Episalvan naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.